Spinal cord injury (SCI) involves complex pathological process which can be complicated by secondary injury. TREK-1 is a member of the two-pore domain potassium (K2P) channel family, which can be modulated by a number of physiological and pathological stimuli. Recent studies suggest that TREK-1 plays an active role in depression, pain and neuroprotection. However, its role in the pathological process after SCI remains unclear. In this study, we tested the expression and function of TREK-1 in spinal cord of mice after traumatic SCI. TREK-1 was widely expressed in mice spinal cord, including astrocytes and neurons. Deficiency of TREK-1 significantly exacerbated focal inflammatory responses as indicated by the increased accumulation of microglia/macrophage as well as proinflammatory factor interleukin-1 beta (IL-1b) and tumor necrosis factor alpha expression. Meanwhile, TREK-1 knockout mice showed enhanced reactive astrogliosis, chondroitin sulphate proteoglycans (CSPGs) production and decreased glutamate transporter-1 expression compared to the wide-type mice after SCI. Furthermore, TREK-1 deficiency promoted neurons and oligodendrocytes apoptosis, aggravated demyelination, cavity formation and retarded motor recovery. In summary, our findings provide the first in vivo evidence suggesting that TREK-1 may thereby constitute a promising therapeutic target to treat acute SCI.
Traumatic spinal cord injury is a devastating and complex clinical condition, which is a major cause of disability (Tohda and Kuboyama 2011) . Axonal regeneration after spinal cord injury is hampered mainly due to an inhibitory environment in the lesion site (Ma et al. 2001; Fitch and Silver 2008) . The secondary injury of spinal cord injury (SCI) is complicated by multiple factors including inflammatory response, glial scar formation, axonal disruption, and glutamate-mediated neurotoxicity (Choo et al. 2008; Ben Borgens and Liu-Snyder 2012) . It is conceivable that sufficient functional recovery may be achieved by combinational therapeutic approaches regulating multiple targets in the secondary damage cascades of SCI (Silver and Miller 2004; Titsworth et al. 2008) .
TREK-1 is a member of newly discovered two-pore domain background potassium channels that are widely expressed in central nervous system (Medhurst et al. 2001; Honore 2007) . Through hyperpolarizing the membrane potential, it tends to reduce excitability and maintain normal neural function (Talley et al. 2001; Honore 2007) . TREK-1 activity is stimulated by a wide range of physiological and pathological inputs including membrane stretch, heat, intracellular acidosis, and cellular lipids (Fink et al. 1998; Patel et al. 1999; Maingret et al. 2000; Liu et al. 2014; Tong et al. 2014) . Accumulating studies have demonstrated that TREK-1 plays a key role in the cellular mechanisms of neuroprotection, anesthesia, pain, and depression (Heurteaux et al. 2004 (Heurteaux et al. , 2006 Alloui et al. 2006) . Recently, TREK-1 has been shown to regulate immune-cell trafficking into the CNS and blood brain barrier function (Bittner et al. 2013 (Bittner et al. , 2014 . However, the roles of TREK-1 in the secondary damage and regeneration after traumatic spinal cord injury have not yet been demonstrated.
Previous studies have indicated that TREK-1 is expressed in both astrocytes and neurons, which could modulate astrocytic homeostatic function and neuronal excitability (Honore 2007; Wu et al. 2013) . It is hypothesized that TREK-1 gene deficiency would contribute to the nonpermissive environment for axonal regeneration, aggravated demyelination, and neuronal death after SCI. In this study, wild-type and TREK-1 gene deficiency homozygote mice were subjected to thoracic weight-drop injury, and the roles of TREK-1 in the secondary events after SCI were investigated. Our results show that TREK-1 knockout can aggravate reactive astrogliosis, inflammatory cascades, neurons and oligodendrocytes apoptosis and inhibit motor functional recovery. These histological and functional outcomes provide valuable evidence suggesting that TREK-1 may be a promising therapeutical target for the treatment of SCI.
Materials and methods

Animals
All the experiments were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee at Tongji Medical College, Huazhong University of Science and Technology. TREK-1 knockout mice were kindly provided from Dr. Min Zhou of Department of Neuroscience, The Ohio State University Wexner Medical Center. The mice were generated on a mixed background of C57BL6J and SV129 strains. All of the second intron, the third exon, and the first 23 bp of the third intron was replaced by a b-galactosidase/neomycin selection cassette (Namiranian et al. 2010) . To confirm this, PCR genotyping (Du et al. 2016) as well as western blot was conducted using tail DNA and spinal cord protein, respectively. All mice were housed in a specific pathogen-free laboratory animal room and given access to a 12-h light-dark cycle in a 18~22°C facility, with free access to food and water. A total of 160 mice including wide-type C57BL/6 and TREK-1 knockout were 8-10 weeks females with a weight of 20-25 g. WT and knockout (KO) mice were randomly assigned into two groups: the sham group, SCI group, using a completely randomized digital table. Observers were blinded to the grouping and experimental design during data collection and analysis.
Surgery
Adult female mice were anesthetized by intraperitoneal injection of 60 mg/kg ketamine and 10 mg/kg promethazine. Once mice were confirmed by toe-pinch to be unconscious, a laminectomy was carried out at T10 level and the vertebral column was stabilized and clamped at the T9 and T11 level. The exposed dorsal surface of the spinal cord was subjected to a 3 g weight drop with 0.5 mm tip diameter of flat surface, at an experimental height of 2 cm using a modified NYU impactor (J&K Seiko Electronic, Dongguan, China). All animals were monitored post-SCI via Basso Mouse Scale (BMS) scoring and urinated twice a day until micturition function recovery.
Tissue preparation Animals in sham, WT SCI, and TREK-1 À/À SCI groups were anesthetized and perfused transcardially with 4% paraformaldehyde in phosphate-buffered saline (PBS) at 1 day, 3 days, 7 days, 14 days, 1 months, 2 months after injury (n = 5 for each time point). Spinal cord tissues containing the injury site (about 2 cm) were harvested and post-fixed overnight at 4°C, then transferred successively to 10% and 30% sucrose-0.01 M PBS for 12-24 h. Finally, the spinal cord tissues were fast frozen in isopentane, cut at 10 lm thickness. The sections were mounted on poly-L-lysinecoated glass slides and stored at À20°C for further analysis.
Immunohistochemical and TUNEL staining
The sections were washed in PBS, blocked in 10% bovine serum albumin solution for 1 h at 25AE5°C. ; 2-3 from rostral left and right and 2-3 from caudal left and right) of gray and white matter were chosen as the injury boundary fields; 4-6 fields at least 10 mm distance from the injury site were chosen as distant fields. The parameters for image capture were set from a wild-type spinal cord and remained constant for all remaining image capturing.
To determine the percentage of neurons and oligodendrocytes apoptosis, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining was performed using the In Situ Cell Death Detection Kit, Fluorescein (Roche, Basel, Switzerland) . Then, the slices were co-stained with rabbit-anti NeuN (1 : 200; Abcam Shanghai, China.) or Olig2 (1 : 200; Merck Millipore), 4 0 ,6-diamidino-2-phenylindole (10 lg/ mL; Sigma-Aldrich). The sections were observed blindly under laser scanning confocal microscope (FV500; Olympus). The total number of TUNEL and NeuN as well as TUNEL and Olig2 double positive cells in five fields near the injury area per section, four sections per animal (n = 4) was counted with ImageJ (National Institute of Health, Bethesda, MD, USA) by a person blinded to the experiment design.
Myelin loss and lesion volume quantification
To detect myelin loss, cryo-sections were stained with Luxol Fast Blue (LFB) and the loss of staining was identified as area of demyelination. Five sections in one animal at interval of 100 lm were selected. Sections in each animal (n = 5) were captured using the Olympus BX51 fluorescent microscope (Olympus). The area of demyelination after SCI was measured with ImageJ software. To assess the lesion volume, eight slices from each animal with 10 lm thickness, 100 lm intervals apart through the dorso-ventral axis of the spinal cord were processed for GFAP immunoreactivity. The volume was quantified employing the Cavalieri's method of Morphometric Volume. Lesion volume = (SUM lesion area 9 distance between sections) À (epicenter lesion area 9 section thickness). All the measurements were made by a specialized person who was blinded to this experiment (Michel and Cruz-Orive 1988; Streijger et al. 2013) .
Western blot analysis
Mice were killed and perfused quickly with 0.9% sterile saline solution at 1 day, 3 days, 7 days, 14 days, 1 month, and 2 months (n = 5 for each time point) after surgery. Spinal cord tissues containing the injury site (about 15 mm) were extracted, and fast frozen in isopentane. Protein extracts were prepared and western blotting was performed as our previous report (Chen et al. 2016) . Samples containing 40 lg total protein were loaded on 12% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After electrophoresis, the proteins were transferred to polyvinylidene difluoride membrane (0.45 lm; Millipore Corporation, Bedford, MA, USA). The membranes were blocked by 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween-20 for 2 h at 25AE5°C. After that, membranes were incubated with primary antibodies including mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1 : 1000; promoter, Wuhan, China), rabbit anti-TREK-1 (1 : 500; Alomone Lab, Jerusalem, Israel), rabbit anti-IL-1b (1 : 500; Abcam, Shanghai, China), rabbit anti-tumor necrosis factor alpha (TNF-a) (1 : 500; Abcam, Shanghai, China), rabbit anti-growth-associated protein-43 (GAP-43) (1 : 5000; Novus Littleton, USA), rabbit anti-GFAP (1 : 2000; Cell Signaling Technology, Beverly, MA, USA), mouse anti-CSPG (1 : 1000; Sigma, St Louis, MO, USA), rabbit anti-glutamate transporter-1 (GLT-1) (1 : 1000; Cell Signaling Technology, Beverly, MA, USA) at 4°C for 12-16 h. Thereafter, horseradish peroxidase conjugated IgG (1 : 6000; Boster, Wuhan, China) were used for 1 h at 25AE5°C. Finally, the blots were visualized by Bio-Rad ChemiDoc XRS+ imaging system using enhanced chemiluminescence kits (Millipore Corporation). The bands were analyzed by a blinder using Image J software to obtain the optical densities (OD) of signals. The value was expressed as the ratio of OD from the tested proteins to OD from GAPDH.
Behavioral studies
The BMS for Locomotion rating scale, from 0 point (no ankle movement) to 9 point (normal gait), was used to evaluate hind limb movement from the day before surgery (Basso et al. 2006; . The mice were evaluated by two researchers blinded to this experiment at the same time and same place for 8 weeks after injury. When the BMS scores of the right hind limbs differ from the left ones, the average of the two scores were taken.
Statistical analysis
All data were expressed as mean AE SEM. Significance of difference between two groups was determined by t-test. For multiple comparisons, one-way or two-way analysis of variance (ANOVA) was followed by Tukey's post hoc test. Data were analyzed using SPSS 13.0 software (IBM, Armonk, NY, USA). Significance was considered at p < 0.05.
Results
Genotyping of TREK-1 Knockout mice
The Tail DNA products from WT and TREK-1 À/À mice were genotyped by PCR, respectively. WT mice show a~450 bp band while TREK-1 KO mice show a~220 bp band (Fig. 1a) . Meanwhile, TREK-1 protein expression in spinal cord was measured from WT and TREK-1 À/À mice using western blot. In WT mice, TREK-1 protein was detected with a molecule weight about 50 KDa. Nevertheless, in TREK-1 KO mice, TREK-1 was rarely observed (Fig. 1b) .
Expression of TREK-1 in the normal and traumatic injured spinal cord tissue As we previously reported, TREK-1 is broadly distributed in the central nervous system, including neurons and astrocytes (Talley et al. 2001) . Here, we investigated the expression of TREK-1 in spinal cord tissue of wide-type mice. The TREK-1 immunoreactivity was broadly detected in spinal cord slice ( Fig. 1ci-iii) . According to the cellular morphology of TREK-1-positive cells, both glia and neurons were labeled. Double immunofluorescent staining demonstrated that the TREK-1 immunoreactivity co-localized well with GFAP positive astrocytes (Fig. 1ciii) and NeuN-positive neurons (Fig. 1cii) . Subsequently, we examined the dynamic changes of TREK-1 protein expression after SCI using western blot. TREK-1 expression was relatively weak in sham mice. After SCI, TREK-1 protein level increased slowly in the first 3 days, which continued to increase to a high level on day 7 and maintained up-regulated up to 2 months after injury compared with sham control (Fig. 1d and e) .
Deficiency of TREK-1 increases reactive gliosis and the secretion of chordroitin sulfate proteoglycans whereas it suppresses GLT1 expression after SCI Reactive astrocytes is a pathologic hallmark of SCI and glial scar acts as a barrier for successful regeneration after SCI (Morgenstern et al. 2002; Fitch and Silver 2008) . Chondroitin sulphate proteoglycans (CSPGs) are extracellular matrix molecules secreted mostly by astrocytes that create a non-permissive environment for axonal growth (Jones et al. 2003) . To study the effect of TREK-1 deficiency on reactive astrogliosis and CSPGs expression, GFAP and CSPGs immunofluorescence staining was performed in sham, WT SCI, and TREK-1 À/À SCI groups. Animals in sham group presented relative low expression of GFAP and CSPGs. In both WT and TREK-1 À/À groups, astrocytes around the lesion site became activated characterized by hypertrophic processes and intense immunoreactivity for GFAP at 14 days and 1 month post injury (Fig. 2a) . Similarly, CSPGs immunoreactivity was up-regulated in regions neighboring traumatic lesions in spinal cord after injury (Fig. 2b) . TREK-1 À/À SCI group showed higher GFAP and CSPG immunoreactivity at 1 month after SCI than WT SCI group ( Fig. 2a  and b) . To confirm our immunofluorescent findings, GFAP and CSPGs protein levels were measured by western blot analysis. In agreement with immunofluorescence results, GFAP and CSGPs protein expression increased significantly on day 14 and day 30 after SCI in both groups compared with sham control while TREK-1 À/À SCI group showed greater GFAP and CSGPs expression on day 30 than WT SCI group (p < 0.05) (Fig. 2c, e and f) . The astrocyte GLT-1 plays an essential role in removing released glutamate from the extracellular space to prevent glutamate-induced excitotoxicity (Lepore et al. 2011) . The protein abundance of glutamate transporters extracted from the peri-traumatic areas was measured by western blot analysis. At day 3 after injury, western blot results showed that the GLT-1 protein level in WT SCI group was upregulated compared with sham control. However, in TREK-1 À/À SCI group, it was down-regulated significantly compared with sham and WT SCI group (3 days p < 0.05; 7 days p < 0.001) ( Fig. 2d and g ).
TREK-1 deficiency promotes the activation of microglia and expression of pro-inflammatory cytokines Microglia activation and inflammatory response contribute to the evolution of secondary degeneration after SCI (Tian et al. 2007; Esposito and Cuzzocrea 2011; Emmetsberger and Tsirka 2012) . The activation of microglia was evaluated by immune-labeling of Iba1 (Ito et al. 1998) . At 3 and 7 days post injury, microglia became activated with hypertrophy of cell body and increased Iba1 immunofluorescence intensity around the lesion site in both WT SCI and TREK-1 À/À SCI group compared with sham control. However, TREK-1 KO mice showed higher Iba1 immunoreactivity than WT group at 3 days (p < 0.01) and 7 days (p < 0.05) ( Fig. 3a and c) . Then, CD68 was labeled to count the number of activated macrophages. SCI induced an obvious increase of CD68 positive cells at day 3 and day 7 after injury. But at day 3 , TREK-1 deficiency induced a significant upregulation in numbers of CD68 + cells surrounding the injury site compared to WT SCI group (p < 0.05) (Fig. 3b and d) .
We next explored the effects of TREK-1 deficiency on pro-inflammatory cytokines production after SCI. IL-1b and TNF-a are the most important inflammatory mediators which could exacerbate secondary cell death and inflammatory reactions (Bartholdi and Schwab 1997) . We examined the IL-1b and TNF-a expression close to the injury epicenter by immunofluorescence staining and western blot analysis. As shown in Fig. 4(a) and (b), IL-1b and TNF-a expressions were low in the sham group. On day 1 after SCI, they increased apparently compared with sham control. TREK-1 deficiency significantly enhanced IL-1b and TNF-a secretion after injury compared with the WT SCI group (p < 0.05) ( Fig. 4c and d) .
TREK-1 deficiency aggravates neurons, oligodendrocytes apoptosis and decreases the expression of growth associated protein-43
We performed TUNEL assay to investigate the effects of TREK-1 knockout on neurons and oligodendrocytes apoptosis in the peri-traumatic areas after SCI. As shown in WT SCI group on day 3 after injury (p < 0.05) (Fig. 5a-d) .
The GAP-43 is a key regulator of axonal growth (Benowitz and Routtenberg 1997) . We detected the GAP-43 expression by immunofluorescence staining and Western blot ( Fig. 5e and f) . At 1 month after injury, WT mice showed no obvious change in GAP-43 protein level compared with sham group. However, the GAP-43 expression was markedly decreased in TREK-1 À/À SCI group in comparison to WT SCI group ( Fig. 5f and g ) (p < 0.05).
TREK-1 deficiency increases volume of the traumatic lesion, area of demyelination and inhibits hind limb motor function recovery after SCI To further investigate the effect of TREK-1 on tissue sparing, lesion volume was quantified on serial cryo-sections labeled against GFAP. The lesion volume was comparable on day 14 after SCI between WT and TREK-1 KO mice. At 1 month, the lesion volume in WT mice was decreased compared with that at day 14, suggesting a spontaneous tissue recovery after SCI. The KO mice showed a larger cavity than wide type at 1 month ( Fig. 6a and c) . The demyelinated area was evaluated by LFB staining. The myelin loss was obvious on day 14 and day 30 after injury. After 1 month, LFB staining deficiency area was larger in TREK-1 KO mice than that in WT mice (p < 0.05) ( Fig. 6b  and d) .
We further studied the influence of TREK-1 deficiency on functional recovery. Scores of motor function were evaluated over 8 weeks using a well-established double-blinded analysis, the BMS scoring (Basso et al. 2006) . Both groups showed a sharp drop in hind limb BMS score in the first day after injury. Then, the animals presented modest improvements of motor function at day 3 after SCI. The recovery continued gradually during the following days. But compared with WT SCI group, TREK-1 À/À SCI mice showed retarded motor function recovery on day 42, day 49 (p < 0.05) and day 56 (p < 0.01) after the injury (Fig. 6e) .
Discussion
TREK-1 is a member of newly discovered two-pore domain background potassium channels which contribute to the background leak K+ currents and regulate neuronal excitability (Piechotta et al. 2011; Vivier et al. 2015) . Accumulating studies have suggested that TREK-1 has a key role in the cellular mechanisms of neurologic disorders such as depression, pain, cerebral ischemia, and experimental autoimmune et al. 2015) . In this study, we found that TREK-1 could participate in multiple-cellular protective effects after SCI. TREK-1 knockout can aggravate reactive astrogliosis, inflammatory cascades, neurons and oligodendrocytes apoptosis and retard motor functional recovery. Reactive astrogliosis is a pathologic hallmark of spinal cord injury (Karimi-Abdolrezaee and Billakanti 2012). Scarforming reactive astrocytes are usually regarded as detrimental to functional restoration and axon regeneration after SCI (Sofroniew 2005; Herrmann et al. 2008) . Approaches in modulation of glial scar have been shown to be effective for endogenous repair and functional recovery after SCI (Tian et al. 2007; Herrmann et al. 2008; Karimi-Abdolrezaee and Billakanti 2012) . CSPGs is a component of glial scar which also exerts inhibitory effect on axonal regeneration after SCI (Silver and Silver 2014; Keough et al. 2016) . As shown in our results, a significant activation of astrocytes, glial scar formation and up-regulated CSGPs expression surrounding the injury site were observed at 1 month after injury. TREK-1 deficiency increased the severity of reactive astrogliosis and the secretion of CSPG S , which may exacerbate tissue loss and function deficit after SCI.
Glutamate-mediated excitotoxicity plays an active role in secondary damage after SCI (Liu et al. 1991; Dugan and Choi 1994) . The astrocyte GLT-1, is responsible for the vast removing of released glutamate from the extracellular spaces in central nervous system (Lepore et al. 2011) . The function of astrocytic electrogenic glutamate transporters are driven by the hyperpolarized membrane potential (Barbour et al. 1988) . TREK-1 contributes to the establishment of the highly negative membrane potential of astrocytes (Zhou et al. 2009 ). Inhibition of TREK-1 activity suppresses the uptake of glutamate by astrocytes under hypoxic conditions (Wu et al. 2013 ). This study shows that an apparent reduction of GLT-1 in knockout mice after SCI compared with WT mice. Correspondingly, the reduction of GLT-1 would promote excitotoxicity and worsen functional and histological outcomes following SCI.
Secondary tissue degeneration and regeneration failure after SCI was substantially mediated by microglia inflammatory responses (Qu et al. 2012; Schwab et al. 2014) . IL-1b and TNF-a are cytokines secreted mostly by activated microglia and macrophage which could complicated the outcomes of SCI (Yune et al. 2003; Sato et al. 2012) . Anti-inflammatory drugs including minocycline and the steroid methylprednisolone have been used to treat SCI and can significantly improve motor and sensory function (Wells et al. 2003; Baptiste and Fehlings 2007) . Recent evidence shows that TREK-1 plays a significant role in regulating inflammatory immune response and function of the blood-brain barrier in an EAE animal model (Bittner et al. 2013) . We have previously shown that TREK-1 activator linolenic acid could inhibit microglia activation after focal ischemia (Liu et al. 2014) . In parallel with these findings, here we found that deficiency of TREK-1 gene significantly exacerbated local inflammatory responses as revealed by the increased microglia activation, IL-1b and TNF-a expression. TREK-1 was rarely detected in microglia by immunofluorescence analysis (data not shown), suggesting that the increase of microgliosis may be indirectly mediated by TREK-1 deficiency induced astrocyte dysfunction and neuronal death. Neurons and oligodendrocytes are very venerable to secondary damage after SCI (Liu et al. 1997; Li et al. 1999; Almad et al. 2011; Teshigawara et al. 2013) . Their death and degeneration in the damage area may contribute to post-injury demyelination and neural circuitry disruption which induces functional impairment (Beattie et al. 2000) . Remyelination and protection of neuronal death are vital to improve axonal regeneration after SCI (McTigue and Tripathi 2008) . Recent research has found TREK-1 participates in linolenic acid-mediated reduction of neuronal apoptosis after focal ischemia (Liu et al. 2014) . In an EAE animal model, a larger demyelination area was found in TREK-1 À/À mice compared WT group (Bittner et al. 2013) .
Our data show that TREK-1 deficiency promoted apoptosis of neurons and oligodendrocytes as well as aggravated myelin loss after SCI. Moreover, this cellular damage was translated into a remarkable behavioral deterioration. In conclusion, we described for the first time the crucial role of TREK-1 in traumatic spinal cord injury. TREK-1 knockout could aggravate reactive astrogliosis, inflammatory cascades, and neuronal apoptosis as well as inhibit motor functional recovery after SCI. Since TREK-1 inhibition may compromise astrocytic homeostatic function (Wu et al. 2013 ) and affect the micro environment which would affect all neurovascular unit elements, the observed pathological changes in TREK-1 null mice may be due to a direct consequence or secondary effect of this K + channel deficiency. Although the complex mechanism is not explicitly clear in this study, our data here suggest that systemic administration of TREK-1 agonist, such as linolenic acid and arachidonic acid, may thus constitute a promising approach for the treatment of acute SCI.
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